ERCC6 and cancer: Notably, platinum-based chemotherapeutic agents, namely Cisplatin and Carboplatin, have favorable responses in cancer with the presence of three driver mutations: PALB2 (p.M723X), BRCA1 (p.Q262H), and ERCC6 (p.M867V).